{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:46:10Z","timestamp":1790934370970,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"French Society of Medical Mycology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>The emergence of azole resistance among Aspergillus fumigatus isolates has driven the development of novel antifungal compounds, which may potentially be used in combination with existing antifungal drugs. In this study, we evaluated the in vitro interaction between olorofim, a novel orotomide antifungal, and voriconazole, a triazole agent, against A. fumigatus using two complementary approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A liquid microdilution checkerboard assay was performed in duplicate on 32 clinical isolates, including 27 voriconazole-susceptible and 5 voriconazole-resistant isolates, to determine the MICs of both drugs alone and in combination. Interactions were quantified using the FIC index and through response surface modelling based on the Bliss independence model. Furthermore, an agar-based method was conducted on a subset of 11 isolates. Media were supplemented with either voriconazole or olorofim, on which discs containing the reciprocal drug were applied. Additionally, interaction was assessed by using Etest\u00ae strips of voriconazole on olorofim-containing agar.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Antagonism was observed for 56% of isolates based on the checkerboard technique and for 75% of the isolates based on response surface analysis. Antagonistic interaction was observed for all the voriconazole-resistant isolates. Across all tested isolates and agar configurations, antagonistic interactions were consistently observed, including reduced inhibition zones around olorofim discs in the presence of voriconazole and paradoxical fungal growth surrounding voriconazole discs or strips on olorofim-containing plates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings demonstrate the in vitro antagonism between olorofim and voriconazole and underscore the need for further investigation before considering their combined clinical use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf393","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T12:05:29Z","timestamp":1760443529000},"page":"3452-3461","source":"Crossref","is-referenced-by-count":6,"title":["Antagonistic\n                    <i>in vitro<\/i>\n                    interaction between olorofim and voriconazole against\n                    <i>Aspergillus fumigatus<\/i>"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8139-8557","authenticated-orcid":false,"given":"Illan","family":"Laloum","sequence":"first","affiliation":[{"name":"Paris-Cit\u00e9 University, Faculty of Medicine , Paris ,","place":["France"]},{"name":"Microbiology Department, Necker Hospital, APHP, Parasitology-Mycology Unit , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Bidaud","sequence":"additional","affiliation":[{"name":"Microbiology Department, Necker Hospital, APHP, Parasitology-Mycology Unit , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8478-2124","authenticated-orcid":false,"given":"Elise","family":"Recalt","sequence":"additional","affiliation":[{"name":"Microbiology Department, Necker Hospital, APHP, Parasitology-Mycology Unit , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0383-1865","authenticated-orcid":false,"given":"Patrick","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Respiratory Medicine, Frankfurt University Hospital , Frankfurt ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4721-2740","authenticated-orcid":false,"given":"Marie-Elisabeth","family":"Bougnoux","sequence":"additional","affiliation":[{"name":"Paris-Cit\u00e9 University, Faculty of Medicine , Paris ,","place":["France"]},{"name":"Microbiology Department, Necker Hospital, APHP, Parasitology-Mycology Unit , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2817-3830","authenticated-orcid":false,"given":"Eric","family":"Dannaoui","sequence":"additional","affiliation":[{"name":"Paris-Cit\u00e9 University, Faculty of Medicine , Paris ,","place":["France"]},{"name":"Microbiology Department, Necker Hospital, APHP, Parasitology-Mycology Unit , Paris ,","place":["France"]},{"name":"Dynamyc Research Group, Paris Est Cr\u00e9teil University (UPEC, EnvA) , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"2025120206225685800_dkaf393-B1","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S2213-2600(21)00442-2","article-title":"Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study","volume":"10","author":"Gangneux","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2025120206225685800_dkaf393-B2","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","article-title":"Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study","volume":"6","author":"Schauwvlieghe","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2025120206225685800_dkaf393-B3","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1056\/NEJMra2027424","article-title":"Aspergillus infections","volume":"385","author":"Thompson","year":"2021","journal-title":"N Engl J Med"},{"key":"2025120206225685800_dkaf393-B4","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"2025120206225685800_dkaf393-B5","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1093\/cid\/ciy859","article-title":"Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study","volume":"68","author":"Lestrade","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025120206225685800_dkaf393-B6","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1093\/jac\/dkz258","article-title":"Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients","volume":"74","author":"Resendiz-Sharpe","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025120206225685800_dkaf393-B7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","article-title":"International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus","volume":"21-22","author":"Verweij","year":"2015","journal-title":"Drug Resist Updat"},{"key":"2025120206225685800_dkaf393-B8","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1128\/CMR.00095-16","article-title":"Molecular tools for the detection and deduction of azole antifungal drug resistance phenotypes in Aspergillus species","volume":"30","author":"Dudakova","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"2025120206225685800_dkaf393-B9","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1093\/jac\/dkac161","article-title":"Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications","volume":"77","author":"Rogers","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2025120206225685800_dkaf393-B10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41579-022-00720-1","article-title":"Tackling the emerging threat of antifungal resistance to human health","volume":"20","author":"Fisher","year":"2022","journal-title":"Nat Rev Microbiol"},{"issue":"Suppl 1","key":"2025120206225685800_dkaf393-B11","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2025120206225685800_dkaf393-B12","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"2025120206225685800_dkaf393-B13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/jof10050345","article-title":"The role of olorofim in the treatment of filamentous fungal infections: a review of in vitro and in vivo studies","volume":"10","author":"Feuss","year":"2024","journal-title":"J Fungi (Basel)"},{"key":"2025120206225685800_dkaf393-B14","doi-asserted-by":"publisher","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025120206225685800_dkaf393-B15","doi-asserted-by":"publisher","first-page":"1291.e7","DOI":"10.1016\/j.cmi.2022.05.013","article-title":"In vitro activity of olorofim against Aspergillus fumigatus sensu lato clinical isolates: activity is retained against isolates showing resistance to azoles and\/or amphotericin B","volume":"28","author":"Escribano","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2025120206225685800_dkaf393-B16","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1093\/jac\/dkae267","article-title":"In vitro activity of olorofim against 507 filamentous fungi including antifungal drug-resistant strains at a tertiary laboratory in Australia: 2020-2023","volume":"79","author":"Halliday","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2025120206225685800_dkaf393-B17","doi-asserted-by":"publisher","first-page":"e01157-17","DOI":"10.1128\/mBio.01157-17","article-title":"Pharmacodynamics of the orotomides against Aspergillus fumigatus: new opportunities for treatment of multidrug-resistant fungal disease","volume":"8","author":"Hope","year":"2017","journal-title":"mBio"},{"key":"2025120206225685800_dkaf393-B18","doi-asserted-by":"publisher","first-page":"106105","DOI":"10.1016\/j.ijantimicag.2020.106105","article-title":"In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus","volume":"56","author":"Kirchhoff","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2025120206225685800_dkaf393-B19","doi-asserted-by":"publisher","first-page":"e01527-20","DOI":"10.1128\/AAC.01527-20","article-title":"Olorofim susceptibility testing of 1,423 Danish mold isolates obtained in 2018-2019 confirms uniform and broad-spectrum activity","volume":"65","author":"Astvad","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206225685800_dkaf393-B20","doi-asserted-by":"publisher","first-page":"e0278922","DOI":"10.1128\/spectrum.02789-22","article-title":"In vitro activity of the novel antifungal olorofim against Scedosporium and Lomentospora prolificans","volume":"11","author":"Georgacopoulos","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2025120206225685800_dkaf393-B21","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3390\/jof7050378","article-title":"In vitro activity of novel antifungal olorofim against filamentous fungi and comparison to eight other antifungal agents","volume":"7","author":"Georgacopoulos","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2025120206225685800_dkaf393-B22","doi-asserted-by":"publisher","first-page":"e0221522","DOI":"10.1128\/mbio.02215-22","article-title":"Antagonism of the azoles to olorofim and cross-resistance are governed by linked transcriptional networks in Aspergillus fumigatus","volume":"13","author":"van Rhijn","year":"2022","journal-title":"mBio"},{"key":"2025120206225685800_dkaf393-B23","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/mmy\/myv029","article-title":"Prospective evaluation of azole resistance in Aspergillus fumigatus clinical isolates in France","volume":"53","author":"Choukri","year":"2015","journal-title":"Med Mycol"},{"key":"2025120206225685800_dkaf393-B24","author":"Arendrup"},{"key":"2025120206225685800_dkaf393-B25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/jof7020113","article-title":"Techniques for the assessment of in vitro and in vivo antifungal combinations","volume":"7","author":"Bidaud","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2025120206225685800_dkaf393-B26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1385\/1-59259-943-5:143","article-title":"Antifungal combinations","volume":"118","author":"Vitale","year":"2005","journal-title":"Methods Mol Med"},{"key":"2025120206225685800_dkaf393-B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2025120206225685800_dkaf393-B28","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"key":"2025120206225685800_dkaf393-B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00224-5","article-title":"Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study","author":"Maertens","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2025120206225685800_dkaf393-B30","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1128\/AAC.48.3.970-978.2004","article-title":"In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus","volume":"48","author":"Dannaoui","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206225685800_dkaf393-B31","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1128\/AAC.00045-12","article-title":"In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus spp","volume":"56","author":"Planche","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206225685800_dkaf393-B32","doi-asserted-by":"publisher","first-page":"e01382-17","DOI":"10.1128\/AAC.01382-17","article-title":"In vitro combination of isavuconazole with echinocandins against azole-susceptible and -resistant Aspergillus spp","volume":"62","author":"Raffetin","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206225685800_dkaf393-B33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/jac\/dks402","article-title":"Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis","volume":"68","author":"Seyedmousavi","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2025120206225685800_dkaf393-B34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"2025120206225685800_dkaf393-B35","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.3201\/eid2911.230984","article-title":"Refractory Microascus bronchopulmonary infection treated with olorofim, France","volume":"29","author":"Faure","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"2025120206225685800_dkaf393-B36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12348-024-00393-2","article-title":"A case of Lomentospora prolificans endophthalmitis treated with the novel antifungal agent olorofim","volume":"14","author":"Dong","year":"2024","journal-title":"J Ophthalmic Inflamm Infect"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3452\/64952845\/dkaf393.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3452\/64952845\/dkaf393.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T11:23:04Z","timestamp":1764674584000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/12\/3452\/8303500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,10,27]]},"published-print":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf393","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,27]]}}}